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Background
According to the cancer stem cell (CSC) hypothesis [1,2], 
tumorigenicity, the capacity to propagate a tumor, is not 
an intrinsic property of any tumor cell, but the deﬁ  ning 
function of a specialized cell-type, the CSC. Within 
individual tumors, only CSCs are able to reform a tumor 
after transplantion in mouse recipients. Notably, these 
tumors have the same cellular heterogeneity as the initial 
one, including both tumorigenic (CSCs) and non-
tumorigenic cells (the remaining cells). CSCs express 
some surface markers of the corresponding normal tissue 
stem cells, while the non-tumorigenic remaining cells 
express markers of progenitors or more diﬀ  erentiated cells.
Th  e existence of a cell hierarchy within tumors is 
shown by CSCs’ ability to reform biologically hetero-
geneous tumors also from single-cell transplantation, 
whereby a CSC generates, through a single asymmetric 
mitotic division, phenocopies of itself (self-renewal) and 
diﬀ  erentiated/non-tumorigenic tumor cells [3].
While the CSC theory lacks deﬁ  nitive proof, it bears 
important implications for cancer treatment. Anti-cancer 
drugs have been selected in early clinical trials for their 
property to reduce tumor size, an eﬀ  ect that reﬂ  ects their 
ability to kill the bulk of tumor cells, but not necessarily 
the rare CSCs. Th   ese might then become the cellular base 
of clinical relapse.
Drugs capable of reducing tumor size and producing 
clinical remission are available for many tumor types. 
Nonetheless, tumors eventually relapse in a large pro  por-
tion of cases, even after long intervals. For instance, in 
mammary tumors relapse rate after chemotherapy and/
or radiotherapy remains very high (up to approximately 
50%) and may occur as late as 30 years after manifestation 
of disease. Th   us, the initial treatment might have spared a 
small population of cells with the ability to survive for 
long periods of time and to re-initiate tumor growth; cells 
that, according to the CSC theory, would be, by deﬁ  ni-
tion, CSCs. Stem cells are generally resistant to cytotoxic 
agents, probably because they are usually non-proli  fera-
ting cells. Are CSCs also chemo- and radio-resistant, thus 
surviving  in vivo treatments and initiating tumor re-
growth? If so, increasing CSC sensitivity to the available 
chemo/radiotherapy treatments becomes a priority.
Article
Th  e work published by Atkinson and colleagues [4] 
demonstrates, in preclinical models of mammary tumors, 
that CSCs are, in fact, resistant to radiotherapy, and that 
their sensitivity dramatically increases with concomitant 
local hyperthermia.
Th  erapeutic hyperthermia involves heating tissues to 
temperatures around 41 to 45°C. While its potential 
beneﬁ  ts in cancer treatment were already acknowledged 
5,000 years ago [5], results from recent clinical trials are 
often controversial, perhaps because of inadequate 
delivery systems, lack of appropriate monitoring of the 
temperature reached by the tumor, or intrinsic limitations 
of conventional heating sources. Notably, a meta-analysis 
of more recent data from randomized clinical trials of 
breast cancer patients, supported by thorough thermo-
metry documentation, demonstrated that hyperthermia 
improves signiﬁ   cantly both local tumor control and 
survival after radiation therapy [6], suggesting that, if 
properly delivered, it is a potent radiation sensitizer. © 2010 BioMed Central Ltd
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Abstract
Tumour relapse is believed to be caused by rare 
cancer-cells with stem-cell properties (cancer stem 
cells) that are intrinsically resistant to available 
treatments. The identifi  cation of novel strategies to 
increase their sensitivity has major clinical implications. 
Latest clinical trials have shown a positive anti-
tumoral eff  ect of hyperthermia in combination with 
chemotherapy or radiotherapy. In a recent paper, the 
combination of increased temperature at the tumour 
site, generated by laser treatment of intravenously-
injected gold nanoshells, and ionizing radiations 
enhances radiosensitivity of cancer stem cells and tumor 
response. At the root of the success of hyperthermia 
in enhancing radio-sensitization of cancer stem cells is 
the inhibition of their capacity to repair DNA damage, 
aff  ecting the survival rate of these cells.
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© 2011 BioMed Central LtdAtkinson and colleagues used an innovative protocol of 
therapeutic hyperthermia based on the use of silica core 
nanoshells associated with thermocouple measurements. 
Nanoparticles are known to passively concentrate in 
tumor tissues after intravenous injection, thus allowing 
enhanced delivery of anticancer agents to malignant cells. 
Th  ose employed in this study were designed to absorb 
light in the near-infrared spectrum and then release 
energy in the form of heat, signiﬁ  cantly increasing the 
intra-tumoral temperature.
Th  e authors used two preclinical model systems of 
breast cancer: the mouse p53-null mammary tumor, 
obtained after transplantation of p53-null mammary cells, 
and xenotransplants of ‘triple-negative’ human mammary 
tumors. Tumor-bearing mice were treated with radio-
therapy alone (single dose) or radiotherapy plus hyper-
ther  mia (concurrently). Local hyperthermia was induced 
by near-infrared illumination of the tumor 24 hours after 
intravenous injection of the nanoparticles, leading to an 
intra-tumoral temperature of 42°C within 5 minutes, 
which persisted for 20 minutes. Mice were sacriﬁ  ced 2 to 
3 days after treatment and tumors analyzed for their CSC 
content, both directly within the tumor (using markers to 
identify CSC-enriched populations) and indirectly by 
their ability to form spheroids in culture or tumors in 
recipient mice upon limiting-dilution transplantation.
Viewpoint
Th  e diﬀ   erent treatment modalities gave comparable 
results in both model systems. Radiotherapy alone 
induced an overall decrease in tumor size, although to 
varying degrees. However, regardless of the degree of 
volume reduction, radiotherapy alone increased the 
relative numbers of CSCs (from 30 to 150%). Notably, 
tumors that re-formed after X-ray treatment (upon trans-
plantation) were more undiﬀ  erentiated tumors. Hyper-
thermia alone did not show signiﬁ  cant eﬀ  ects on tumor 
size or frequency of CSCs. Th  e combination of X-rays 
plus hyperthermia, however, caused a greater regression 
of tumor size than the ionizing-radiation treatment 
alone, and, remarkably, a signiﬁ  cantly lower percentage 
of CSCs. Accordingly, after the combination treatment, 
re-growing tumors appeared more diﬀ  erentiated.
Th  us, CSCs are resistant to X-rays and are selected 
during treatment in vivo. Th   ese results indirectly suggest 
that resistant CSCs are responsible for tumor re-growth 
after-treatment, or, at least, that the re-formed tumors 
tend to lose their most diﬀ  erentiated component. Th  ey 
also show that hyperthermia, although ineﬀ  ective  by 
itself, increases the eﬀ  ect of X-rays on tumor growth by 
increasing CSC sensitivity to them.
Th  is study also provides insights into the molecular 
mechanisms underlying the sensitizing eﬀ  ect of hyper-
thermia. Th   e cytotoxic eﬀ  ect of X-rays is mainly due to 
induction of DNA double-strand breaks. While it was 
already known that CSCs are resistant to X-rays due to 
their unique ability to repair DNA damage, the authors 
show that hyperthermia diminishes this ability. It is likely, 
therefore, that, in the presence of hyperthermia, X-rays 
induce excess DNA damage and CSC death. It was 
recently shown that inactivation of DNA repair pathways 
causes DNA-damage ‘overloading’ in leukemia stem cells 
[7], leading to their functional exhaustion and preventing 
the development of the tumor clone. Th  us, a growing 
body of evidence links CSC inherent resistance to DNA 
damage to tumorigenicity and to their resistance to 
currently available cytotoxic drugs. Th  e  identiﬁ  cation of 
treatment modalities, including hyperthermia, that 
counteract the intrinsic capacity of CSCs to survive DNA 
damage emerges as a new promising strategy to target 
tumor growth and prevent tumor relapse.
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